Biopharmaceutical company Viking Therapeutics Inc (NASDAQ:VKTX) disclosed on Tuesday the addition of Kathy Rouan, PhD to its board of directors.

As a member of the board, Dr Rouan provides the company with drug discovery and development expertise across a broad range of therapeutic areas including gastroenterology, cardiovascular, immune-inflammation and oncology.

Most recently, Dr Rouan has served as senior vice president and head of Projects, Clinical Platforms and Sciences (PCPS) as well as vice president and head of metabolism and pulmonary project management at GlaxoSmithKline (GSK), which she joined in 1989.

Currently, Dr Rouan is a member of the board of directors of Navidea Pharmaceuticals.